ResearchMoz

Dialysis Partnering 2007-2013

Current Partnering
Published Date » 2013-07-01
No. Of Pages » 100
   
 The Dialysis Partnering  2007-2013 provides understanding and access to the dialysis partnering deals and agreements entered into by the worlds leading healthcare companies. 
   
 The report provides an analysis of dialysis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dialysis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 
   
 Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of...
Table of Content

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in dialysis partnering
2.1. Introduction
2.2. Dialysis partnering over the years
2.3. Bigpharma dialysis dealmaking activity
2.4. Dialysis partnering by deal type
2.5. Dialysis partnering industry sector
2.6. Dialysis partnering by stage of development
2.7. Dialysis partnering by technology type
2.8. Disclosed financial deal terms for dialysis partnering
2.8.1 Dialysis headline values
2.8.2 Dialysis upfront payments
2.8.3 Dialysis milestone payments
2.8.4 Dialysis royalty rates

Chapter 3 Leading dialysis deals
3.1. Introduction
3.2. Top dialysis deals by value
3.3. Top dialysis deals involving bigpharma

Chapter 4 Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines

Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports

List of Tables

NA

List of Figures


Figure 1: Dialysis partnering since 2007 
Figure 2: Bigpharma top 50 dialysis deals 2007 to 2011 
Figure 3: Bigpharma dialysis deal frequency 2007 to 2011 
Figure 4: Dialysis partnering by deal type since 2007 
Figure 5: Dialysis partnering by industry sector since 2007 
Figure 6: Dialysis partnering by stage of development since 2007 
Figure 7: Dialysis partnering by technology type since 2007 
Figure 8: Dialysis deals with a headline value 
Figure 9: Dialysis deals with upfront payment values 
Figure 10: Dialysis deals with milestone payments 
Figure 11: Dialysis deals with royalty rates, % 
Figure 12: Top dialysis deals by value since 2007 
Figure 13: Top dialysis deals signed by bigpharma value since 2007 
Figure 14: Online partnering resources 
Figure 15: Forthcoming partnering events 
Figure 16: Deal type definitions

Upcoming Reports:

Greece: market of rusks, toasted bread and similar toasted products
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the rusks, toasted bread and similar toasted products market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the rusks, toasted bread and similar toasted products market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development...
Poland: floor mats market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the floor mats market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the floor mats market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
High Performance Rubber Market: Industry Analysis, Market Size, Share, Trends, Growth And Forecast 2010 - 2018
By - Transparency Market Research
Products such as neodymium-based performance butadiene rubber (Nd-PBR) and solution styrene butadiene rubber (S-SBR) are chief ingredients of high performance rubber. These products represent the family of synthetic rubbers derived from styrene and butadiene. Nd-PBR is chiefly used in manufacturing the treads and side walls of "Green Tires" whereas S-SBR is used as the chief tread compound of "Green Tires". Addition of these products makes tires safe, lessens rolling resistance, improves grip on wet road and increases fuel efficiency, provides high resistance to abrasion and thus...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...